Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$4.27 USD
-0.22 (-4.79%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.26 -0.01 (-0.23%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VYGR 4.27 -0.22(-4.79%)
Will VYGR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for VYGR
Stochastic Reached Overbought appears for VYGR after 5.28% move
VYGR forms Shooting Star Candlestick on September 17
VYGR's price rises by 0.95% on September 16, though its technical setup remains stable.
Is VYGR poised for gains? 200 Day Moving Average Support shows up after rising 0.72%
VYGR Makes Notable Cross Below Critical Moving Average